Correlation Between Salesforce and Tscan Therapeutics

Can any of the company-specific risk be diversified away by investing in both Salesforce and Tscan Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Salesforce and Tscan Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Salesforce and Tscan Therapeutics, you can compare the effects of market volatilities on Salesforce and Tscan Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Salesforce with a short position of Tscan Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Salesforce and Tscan Therapeutics.

Diversification Opportunities for Salesforce and Tscan Therapeutics

0.81

Correlation Coefficient

Salesforce  Tscan Therapeutics

Very poor diversification

The 3 months correlation between Salesforce and Tscan is 0.81. Overlapping area represents the amount of risk that can be diversified away by holding Salesforce and Tscan Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Tscan Therapeutics and Salesforce is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Salesforce are associated (or correlated) with Tscan Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Tscan Therapeutics has no effect on the direction of Salesforce i.e., Salesforce and Tscan Therapeutics go up and down completely randomly.

Pair Corralation between Salesforce and Tscan Therapeutics

Considering the 90-day investment horizon Salesforce is expected to generate 0.43 times more return on investment than Tscan Therapeutics. However, Salesforce is 2.35 times less risky than Tscan Therapeutics. It trades about -0.18 of its potential returns per unit of risk. Tscan Therapeutics is currently generating about -0.28 per unit of risk. If you would invest  33,574  in Salesforce on December 29, 2024 and sell it today you would lose (6,577) from holding Salesforce or give up 19.59% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Salesforce  vs.  Tscan Therapeutics

Salesforce

Risk-Adjusted Performance

Very Weak

Over the last 90 days Salesforce has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Tscan Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Tscan Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Salesforce and Tscan Therapeutics

The main advantage of trading using opposite Salesforce and Tscan Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Salesforce position performs unexpectedly, Tscan Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tscan Therapeutics will offset losses from the drop in Tscan Therapeutics' long position.

The idea behind Salesforce and Tscan Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.